Scotland issues new framework to help reduce the risk of developing type 2 diabetes

Scotland issues new framework to help reduce the risk of developing type 2 diabetes

July 20 2018 A new framework emphasising weight management as part of the drive to reduce the...

MHRA issues reminder to use Yellow Card reporting for suspected ADRs associated with pregnancy

MHRA issues reminder to use Yellow Card reporting for suspected ADRs associated with pregnancy

July 19 2018 The medicines regulator has issued a Drug Safety Update relating to suspected...

APPG calls for long term conditions to be part of new pharmacy contract

APPG calls for long term conditions to be part of new pharmacy contract

July 16 2018 Community pharmacy’s involvement in managing long term conditions should be...

NICE updates guideline on rheumatoid arthritis

NICE updates guideline on rheumatoid arthritis

July 13 2018 NICE has issued a new version of its guideline on the management of rheumatoid...

RPS seeks views on draft guidance around polypharmacy

RPS seeks views on draft guidance around polypharmacy

July 13 2018 The Royal Pharmaceutical Society is seeking comments to hone draft guidance on...

  • Scotland issues new framework to help reduce the risk of developing type 2 diabetes

    Scotland issues new framework to help reduce the risk of developing type 2 diabetes

    Friday, 20 July 2018 14:36
  • MHRA issues reminder to use Yellow Card reporting for suspected ADRs associated with pregnancy

    MHRA issues reminder to use Yellow Card reporting for suspected ADRs associated with pregnancy

    Thursday, 19 July 2018 10:29
  • APPG calls for long term conditions to be part of new pharmacy contract

    APPG calls for long term conditions to be part of new pharmacy contract

    Monday, 16 July 2018 15:44
  • NICE updates guideline on rheumatoid arthritis

    NICE updates guideline on rheumatoid arthritis

    Friday, 13 July 2018 12:51
  • RPS seeks views on draft guidance around polypharmacy

    RPS seeks views on draft guidance around polypharmacy

    Friday, 13 July 2018 12:47

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

drugalertJune 27 2016

The tablet and oral suspension preparations of Noxafil (posaconazole) are not interchangeable, the European Medicines Agency has warned. Due to the formulations not having the same pharmacokinetics, there are concerns that patients may be receiving an ineffective dose or overdose if there has been a change from the prescribed formulation.

EMA issued the warning on Friday saying that Noxafil is available as 100mg tablets or as a 40mg/ml oral suspension. The drug is indicated for a number of fungal infections where other antifungal agents are ineffective or not suitable for use, and for prophylactic use in certain other circumstances.

“The recommended oral dosage is 300 mg once a day with the tablets (after a loading dose of 300 mg twice daily on day 1) and 200 mg three to four times a day (600 to 800 mg daily) with the oral suspension,” said EMA. “Medication errors have been reported following erroneous switching, resulting in over or under-dosage and consequent dose-related toxicity or lack of efficacy.

“It is important that the dosage form as well as the relevant dose be specified on the prescription, and that pharmacists ensure the correct oral dosage form is dispensed.”

EMA has said that the Summary of Product Characteristics (SmPC) and patient information leaflet (PIL) for Noxafil are being updated to strengthen warnings about the differences between the two formulations. In addition, “the outer cartons will be revised to further differentiate the two and to include a warning statement that they cannot be simply substituted without adjusting the dose.”

It will be writing to health professionals to remind them of the issue.

Link:

EMA announcement

Practice News

July 20 2018 A consultation asking for views on how the safety features required under the Falsified Medicines Directive should be implemented has been issued.
July 20 2018 A consultation asking for views on how the safety features required under the Falsified Medicines Directive should be implemented has been issued. The MHRA has launched the consultation with...